Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial-Reference-Cited by-同舟云学术

Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial

Published:2017-11-17 Issue:1 Volume:17 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Shiroiwa Takeru,Fukuda Takashi,Shimozuma Kojiro,Mouri Mitsuko,Hagiwara Yasuhiro,Kawahara Takuya,Ohsumi Shozo,Hozumi Yasuo,Sagara Yoshiaki,Ohashi Yasuo,Mukai Hirofumi

Funder

Comprehensive Support Project for Oncology Research (CSPOR) of the Public Health Research Foundation

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-017-3774-7.pdf

Reference28 articles.

1. Burki TK. NICE restructures the cancer drugs fund. Lancet Oncol. 2016;17(1):e9.

2. Timmins N. At last, NICE to take over the cancer drugs fund. BMJ. 2016;352:i1324.

3. Squires H, Stevenson M, Simpson E, Harvey R, Stevens J. Trastuzumab Emtansine for treating HER2-positive, Unresectable, locally advanced or metastatic breast cancer after treatment with Trastuzumab and a Taxane: an evidence review group perspective of a NICE single technology appraisal. PharmacoEconomics. 2016;34(7):673–80.

4. Wade R, Duarte A, Simmonds M, Rodriguez-Lopez R, Duffy S, Woolacott N, Spackman E. The clinical and cost effectiveness of Aflibercept in combination with Irinotecan and fluorouracil-based therapy (FOLFIRI) for the treatment of metastatic colorectal cancer which has progressed following prior Oxaliplatin-based chemotherapy: a critique of the evidence. PharmacoEconomics. 2015;33(5):457–66.

5. Greenhalgh J, Bagust A, Boland A, Oyee J, Trevor N, Beale S, Dundar Y, Hockenhull J, Proudlove C, O'Reilly S. Eribulin for the treatment of advanced or metastatic breast cancer: a NICE single technology appraisal. PharmacoEconomics. 2015;33(2):137–48.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Eribulin versus S-1 as first or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomised, controlled, open-label, phase 3 trial;eClinicalMedicine;2024-08

2. Efficacy of S-1 Adjuvant Chemotherapy for Resected Biliary Tract Cancer: A Retrospective Propensity-Matched Analysis;The American Surgeon™;2024-01-16

3. Inhibition of Janus Kinase 2/Signal Transducer and Activator of Transcription 3 Pathway Sensitization of LoVo Cells After 5-Chloro-2,4-Dihydroxypyridine Based 5-Fluorouracil Treatment;Nanoscience and Nanotechnology Letters;2018-07-01